Drug-induced autoimmune hepatitis associated with turmeric dietary supplement use

Abstract

Turmeric dietary supplement sales, which accounted for US$69 million in spending in 2016, have been increasing exponentially in the USA, making this one of the most popular botanical supplements sold in the USA. Herbal supplement use, which is generally regarded as safe by consumers, is not usually reported to healthcare providers. We reported here on a case of autoimmune hepatitis, occurring in a 71-year-old woman taking turmeric dietary supplements for the maintenance of cardiovascular health, which resolved rapidly following discontinuation of the turmeric supplements. Of particular note, turmeric use was not documented in the patient's medical records and the potential causative role of the turmeric supplementation was ultimately identified by the patient rather than the healthcare providers. To our knowledge, this is the first documented report of turmeric supplement-induced autoimmune hepatitis.

A rare case of turmeric‐induced hepatotoxicity

“…While touted for its many benefits, including paradoxically, anti‐inflammatory effect in non‐alcoholic steatohepatitis, this case illustrates the significant risk of hepatotoxicity associated with turmeric. To date, there has been only one other case reported in current literature to support this finding . Our case highlights the importance of clinicians and consumers to remain diligent of adverse effects when utilising natural or alternative medicines.…”

Turmeric Induced Liver Injury: A Report of Two Cases

“…Regarding adverse effects, a number of severe adverse effects have been reported when given orally [16–18], topically [19], vaginally [20], and intravenously [21]. Mild liver function test derangement has been reported in approximately 5% of cases in randomized controlled trials [22], with one report of drug induced autoimmune hepatitis reported recently [22]. The potential for drug interactions has been recognized, with dose-dependent inhibition of cytochrome p450 subtypes CYP3A4 and CYP1A2 in the liver [23] and intestines [24] identified.…”

Obstacles against the Marketing of Curcumin as a Drug

“…Moreover, recent reports of liver diseases related to curcumin attracted the medical community's attention to its possible hepatotoxicity [203]. Whether this effect belongs to curcumin molecule or other possible contamination has to be elucidated.…”